"Piper Jaffray's newfound bullishness on Array BioPharma (ARRY) puts the stock on the brink of a 5-month high as the investment bank expresses optimism about study data due from ARRY later this year. In addition, the company "has several partnering opportunities in 2013 that could bring in nondilutive funding," an always-welcome sentiment for shareholders. Piper, which boost its price target on ARRY to $7 from $4, notes the company finished 2012 with $110M of cash, which it estimates would get ARRY through mid-2014."
What did the boy cheese say to his cheese girl friend? "Looking gouda!"